Bayer AG buys herbal medicine company; Novartis is not interested in Actavis;

@FiercePharma: Another pharma deal: Sweden's Recipharm mulls IPO or partial sale, Reuters says. UBS advising. News | Follow @FiercePharma

@EricPFierce: EMA committee backs Bayer's Diane-35 birth control drug, even as off-label acne treatment. Article | Follow @EricPFierce

> Novartis ($NVS) knocked down reports that it was looking at buying generic drugmaker Actavis ($ACT) by publicly saying it was not interested. Report

> Germany's Bayer has bought herbal medicine company Steigerwald Arzneimittelwerk, also a Germany-based company. Report

> The National Institutes of Health (NIH) is looking at how more can be done to fight opioid abuse and is suggesting social media can play a part. Story

> Drugmaker Hikma says it will no longer sell phenobarbital to Arkansas after learning it was being used for executions. Story

> The Biogen Idec ($BIIB) Foundation is making a $250,000 grant to a program in England intended to create an interactive program for young people in Cambridge to learn about genetics. Item 

> Impax Laboratories Inc. ($IPXL) said Friday it is now selling a generic version of the migraine drug Zomig. Story

Medical Device News

@FierceMedDev: Shorter Tryton side branch stent wins CE mark. Article | Follow @FierceMedDev

@MarkHFierce: J&J is leaving the metal hip replacement business behind. Bloomberg broke a good one: Report | Follow @MarkHFierce

 @DamianFierce: Quest buys Humana's toxicology and clinical lab business. News | Follow @DamianFierce

> Thoratec wins FDA nod for HeartMate controller. Report

> Thermedical scores $5.5M in funding for tumor, heart ablation research. Item

> Vascular Solutions sues Boston Scientific for 'blatant' patent infringement. News

Biotech News

@FierceBiotech: PPD's BioDuro opens Shanghai discovery lab. FierceCRO story | Follow @FierceBiotech

@JohnCFierce: Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Report | Follow @JohnCFierce

@RyanMFierce: PTC, bluebird join the IPO frenzy in biotech with genetic therapies. Story | Follow @RyanMFierce

> Sanofi balks on jobs promises at R&D site in Toulouse. Report

> Novo Nordisk completes PhIII hemophilia trial with positive results. Item

> AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot. News

And Finally... In its official rejection of a $5.7 billion buyout offer from Royalty Pharma, Irish drug company Elan said Royalty made its bid after first suggesting Elan buy Royalty out. Story

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.